Ticker

NEW YORK--(BUSINESS WIRE)--KKR Income Opportunities Fund (the “Fund”) (NYSE: KIO) today announced its monthly distributions of $0.1215 per common share, payable on the dates below. Based on the Fund's current share price of $10.97 per share (as of market close on September 9, 2026), the distributions represent an annualized distribution rate of 13.29% (calculated by annualizing the distribution amount and dividing…

Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD). CKD, based in Seoul, is one of South Korea's leading pharmaceutical companies.

KKR Income Opportunities Fund (NYSE: KIO - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $11.24 and traded as low as $11.20. KKR Income Opportunities Fund shares last traded at $11.2130, with a volume of 366,158 shares traded. KKR Income

The KKR Income Opportunities Fund offers a 12.95% yield but has suffered NAV and price declines, raising concerns about distribution sustainability. KIO's portfolio blends floating-rate senior loans and fixed-rate junk bonds, positioning it to benefit modestly from potential Fed rate hikes. Recent performance has lagged peers, with the fund paying out more than it earns, leading to destructive distributions and NAV…

Data Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in Epileptiform Activity: KIO-300 is the active pharmaceutical ingredient of KIO-301, Kiora's ongoing Phase 2 clinical program in vision restoration in patients with gene mutation-agnostic Retinitis Pigmentosa Encinitas, California--(Newsfile Corp. - June 18, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced…